Literature DB >> 6761865

The comparative pharmacology of cyclophosphamide and ifosfamide.

M Colvin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6761865

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  14 in total

1.  Basic principles in preclinical cancer chemotherapy.

Authors:  N Brock; J Pohl; B Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 4.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

5.  Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.

Authors:  P A Philip; L D Lewis; C A James; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs.

Authors:  A S Ensslin; Y Stoll; A Pethran; A Pfaller; H Römmelt; G Fruhmann
Journal:  Occup Environ Med       Date:  1994-04       Impact factor: 4.402

7.  Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.

Authors:  O Tofanetti; E Cavalletti; A Besati; G Pratesi; G Pezzoni; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.

Authors:  C I Falkson; H C Falkson; G Falkson
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

9.  Ifosfamide in pediatric malignant solid tumors.

Authors:  C B Pratt; E C Douglass; E L Etcubanas; M P Goren; A A Green; F A Hayes; M E Horowitz; W H Meyer; E I Thompson; J A Wilimas
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.

Authors:  G P Sutton; J A Blessing; L Adcock; K D Webster; T DeEulis
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.